SDHB
- Known as:
- SDHB
- Catalog number:
- Y213462
- Product Quantity:
- 200ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- SDHB
Related genes to: SDHB
- Gene:
- SDHB NIH gene
- Name:
- succinate dehydrogenase complex iron sulfur subunit B
- Previous symbol:
- SDH1, SDH
- Synonyms:
- -
- Chromosome:
- 1p36.13
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: SDHB
anti-SDHBanti-SDHBanti-SDHB (C-Terminus)Anti-SDHB Antibodyanti-SDHB type: Primary antibodies host: RabbitAnti-SDHB, Goat Polyclonal to SDHB, Isotype , Host GoatAntibodies: SDHB HOST: Goat Clonality: pAbBos taurus,Bovine,IP,Iron-sulfur subunit of complex II,SDHB,Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrialBovine succinate dehydrogenase complex, subunit B, iron sulfur (Ip) (SDHB) ELISA kit, Species Bovine, Sample Type serum, plasmaBovine Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial(SDHB) ELISA kitBovine Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial(SDHB) ELISA kitBovine Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial(SDHB) ELISA kit SpeciesBovineCanine Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial(SDHB) ELISA kitCanine Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial(SDHB) ELISA kitChicken succinate dehydrogenase complex, subunit B, iron sulfur (Ip) (SDHB) ELISA kit, Species Chicken, Sample Type serum, plasma Related articles to: SDHB
- Simultaneous targeting of glycolysis and oxidative phosphorylation (OXPHOS) is an effective strategy for overcoming the metabolic plasticity of pancreatic ductal adenocarcinoma (PDAC). In this study, we present compound , a rationally designed, mitochondria-targeted small molecule that disrupts PDAC energy metabolism. Compound markedly inhibited PDAC cell glycolysis and mitochondrial function, as evidenced by the PDKs inhibition and the downregulation of OXPHOS-associated proteins, including SDHB and SIRT3, in vitro and in vivo. Mechanistically, induced ferroptotic cell death, accompanied by lipid peroxidation, redox imbalance, and mitochondrial dysfunction. Importantly, also elicited hallmarks of immunogenic cell death (ICD), including calreticulin exposure and HMGB1 release. In a syngeneic PANC02 model, suppressed tumor growth with minimal systemic toxicity and recapitulated the metabolic inhibition and ICD-associated phenotypes observed in vitro. These findings support that could be used as a dual metabolic inhibitor and ICD inducer in PDAC therapy. - Source: PubMed
Publication date: 2026/05/21
Yan HaiboLi DongshengYang MinXu MingyangYang YingDai ZhenzhenOu JiaminHe YunXu BiaoZhang Shao-Lin - -related pheochromocytoma and paraganglioma (PPGL) are associated with a high risk of metastasis. Minimal data are available on these genetically based tumors from the Middle East. - Source: PubMed
Publication date: 2026/04/15
Alzahrani Ali SAlghamdi BalgeesBenito AllianahMohamed Gamal - Malignant carotid body tumor (CBT), a type of carotid body paraganglioma (PGL), is defined by the presence of distant metastasis; histology alone cannot reliably distinguish benign from malignant CBT. We present a 70-year-old female patient who had been suspected of having CBT for more than 10 years without specific treatment, and complained of abdominal pain for 6 months. Contrast-enhanced MRI and CT revealed a T11 vertebral lesion, followed by percutaneous biopsy of the lesion, which showed atypical cell nests. Immunohistochemical staining was positive for CD56, CgA, Syn and S-100, and negative for cytokeratin. A diagnosis of metastatic PGL consistent with malignant CBT was established. The patient received palliative radiotherapy to the T11 vertebra (20 Gy/5 fractions), which was well tolerated without obvious radiation-related adverse reactions. At the 12-month follow-up, the patient remained alive. - Source: PubMed
Publication date: 2026/05/20
Li FeiYang JieZhang JuanZhao MengfanQie ShuaiZang Shasha - To investigate somatic pathogenic variants (PVs) in the TERT promoter region and variants in the ATRX gene, both related to telomere maintenance in cancer, in a Brazilian cohort of adrenal and extra-adrenal paragangliomas (PPGLs), and to correlate these with metastatic disease as well as with clinical, radiological, and pathological characteristics. - Source: PubMed
Publication date: 2026/08/01
Batini LucasLobato Eduardo CFreitas-Castro FelipeSantana Lucas SFagundes Gustavo F CAfonso Ana Caroline FNakamura Izabel TRossetti Lucas BMendonca Berenice BLatronico Ana ClaudiaAlmeida Madson Q - Renal cell carcinoma (RCC) associated with BRCA2 mutation is an extremely rare but increasingly recognized tumor type with characteristic but variable morphological features and aggressive behavior. We report a new case of high‑grade RCC harboring a somatic BRCA2 mutation in a 69‑year‑old male presenting with painless gross hematuria. The tumor exhibited a complex admixture of solid papillary/alveolar, cribriform, and tubulocystic architectures with prominent eosinophilic nucleoli. A biphasic pattern was observed, with central nests of more bland clear cells forming rosette‑like structures around hyaline basement membrane material, a finding reminiscent of TFEB‑altered RCC. Immunohistochemically, the tumor showed a nonspecific immunophenotype with expression of PAX8, CD10, and vimentin, while other RCC‑associated markers were negative. SMARCB1/INI1, SDHB, and FH expression were retained. Targeted next‑generation sequencing confirmed a somatic BRCA2 truncating mutation and absence of alterations in VHL, MET, TSC1/2/MTOR, SDHx, FH, or MiTF genes. A review of all five previously reported BRCA2‑associated RCCs revealed that all six reported cases (including ours) shared certain features: mixed papillary and solid architecture, high‑grade cytology with prominent nucleoli, and absence of other RCC‑defining molecular drivers. Our case not only reinforces the previously reported features but also expands the morphological spectrum of BRCA2‑associated RCC, providing further evidence that this may represent a distinct subtype of RCC. - Source: PubMed
Publication date: 2026/05/19
Wang YingjingYin XiaonaXia ChengqingZhao Ming